Renal Denervation: An Update

Sinny Delacroix, Ramesh Girish Chokka, Adam Nelson, Stephen J. Nicholls, Stephen G. Worthley


Resistant hypertension is a growing cardiovascular problem worldwide and despite significant pharmacological advances medical management of the pathology remains challenging. In early clinical trials renal denervation, a catheter based therapy that denervates renal afferent and efferent sympathetic nervous system has demonstrated significant blood pressure reduction in patients with resistant hypertension. However, Symplicity HTN-3, the recent randomized controlled trial has challenged the efficacy of the procedure and underscored that there remain key issues to overcome before the procedure can be used as a standard of care in patients with resistant hypertension. This review provides a balanced update on the recent preclinical and clinical studies in the field and, focuses on the important advances required to enhance the forward progression of a technique that has the potential to treat this highly heterogenous pathology.

Full Text:



Hypertension. World Heart Foundation. 2014.

Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK and He J. Global burden of hypertension: analysis of worldwide data. Lancet. 2005;365:217-23.

Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, White A, Cushman WC, White W, Sica D, Ferdinand K, Giles TD, Falkner B, Carey RM and American Heart Association Professional Education C. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation. 2008;117:e510-26.

Persell SD. Prevalence of Resistant Hypertension in the United States, 2003-2008. Hypertension. 2011;57:1076-1080.

Neal B, MacMahon S, Chapman N and Blood Pressure Lowering Treatment Trialists C. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration. Lancet. 2000;356:1955-64.

Evelyn KA, Alexander F and Cooper SR. Effect of sympathectomy on blood pressure in hypertension; a review of 13 years' experience of the Massachusetts General Hospital. J Am Med Assoc. 1949;140:592-602.

Smithwick RH and Thompson JE. Splanchnicectomy for Essential Hypertension - Results in 1,266 Cases. Jama-J Am Med Assoc. 1953;152:1501-1504.

Stella A and Zanchetti A. Functional role of renal afferents. Physiol Rev. 1991;71:659-82.

Barajas L, Liu L and Powers K. Anatomy of the renal innervation: intrarenal aspects and ganglia of origin. Canadian journal of physiology and pharmacology. 1992;70:735-49.

DiBona GF and Kopp UC. Neural control of renal function. Physiol Rev. 1997;77:75-197.

Ciriello J and de Oliveira CV. Renal afferents and hypertension. Curr Hypertens Rep. 2002;4:136-42.

Huysmans FTM, Vanheusden FHJA, Wetzels JFM, Hoitsma AJ and Koene RAP. Antihypertensive Effect of Beta Blockade in Renal-Transplant Recipients with or without Host Kidneys. Transplantation. 1988;46:234-237.

Converse RL, Jacobsen TN, Toto RD, Jost CMT, Cosentino F, Fouadtarazi F and Victor RG. Sympathetic Overactivity in Patients with Chronic-Renal-Failure. New Engl J Med. 1992;327:1912-1918.

Ligtenberg G, Blankestijn PJ, Oey PL, Klein IHH, Dijkhorst-Oei LT, Boomsma F, Wieneke GH, van Huffelen AC and Koomans HA. Reduction of sympathetic hyperactivity by enalapril in patients with chronic renal failure. New Engl J Med. 1999;340:1321-1328.

Hausberg M, Kosch M, Harmelink P, Barenbrock M, Hohage H, Kisters K, Dietl KH and Rahn KH. Sympathetic nerve activity in end-stage renal disease. Circulation. 2002;106:1974-1979.

Esler M. The sympathetic system and hypertension. American journal of hypertension. 2000;13:99S-105S.

Quinby WC. The function of the kidney when deprived of its nerves. J Exp Med. 1916;23:535-U21.

Kottke FJ, Kubicek WG and Visscher MB. The Production of Arterial Hypertension by Chronic Renal Artery-Nerve Stimulation. American Journal of Physiology. 1948;145:38-47.

Abramczyk P, Zwolinska A, Oficjalski P and Przybylski J. Kidney denervation combined with elimination of adrenal-renal portal circulation prevents the development of hypertension in spontaneously hypertensive rats. Clinical and experimental pharmacology & physiology. 1999;26:32-4.

Bertog SC, Sobotka PA and Sievert H. Renal denervation for hypertension. JACC Cardiovascular interventions. 2012;5:249-58.

Wu XY, Scholey JW, Sonnenberg H and Melo LG. Renal vascular morphology and haemodynamics in Dahl salt-sensitive rats on high salt-low potassium diet: neural and genetic influences. J Hypertens. 2000;18:783-793.

Hollenberg NK, Williams GH and Adams DF. Essential-Hypertension - Abnormal Renal Vascular and Endocrine Responses to a Mild Psychological Stimulus. Hypertension. 1981;3:11-17.

Krum H, Schlaich M, Whitbourn R, Sobotka PA, Sadowski J, Bartus K, Kapelak B, Walton A, Sievert H, Thambar S, Abraham WT and Esler M. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet. 2009;373:1275-1281.

Fischell T, Vega F, Kent DJ, Bertog SC, Raju N, Ladich E, Yahagi K, Virmani R and Ghazarossian VE. Transcatheter Perivascular Chemical Neurolysis to Produce Renal Denervation: Targeted, Local Delivery of Alcohol as a Viable Alternative to Radiofrequency Approaches. J Am Coll Cardiol. 2015;66:B40-B41.

Fischell TA, Vega F, Raju N, Johnson ET, Kent DJ, Ragland RR, Fischell DR, Almany SL and Ghazarossian VE. Ethanol-mediated perivascular renal sympathetic denervation: preclinical validation of safety and efficacy in a porcine model. Eurointervention. 2013;9:140-7.

Medical K. Kona Medical Announces Initiation of WAVE I Study of Renal Denervation Therapy for Hypertension. 2012;2015.

Waksman R, Barbash IM, Chan R, Randolph P, Makuria AT and Virmani R. Beta radiation for renal nerve denervation: initial feasibility and safety. Eurointervention. 2013;9:738-744.

Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, Boehm M, Mahfoud F, Sievert H, Wunderlich N, Rump LC, Vonend O, Uder M, Lobo M, Caulfield M, Erglis A, Azizi M, Sapoval M, Thambar S, Persu A, Renkin J, Schunkert H, Weil J, Hoppe UC, Walton T, Scheinert D, Binder T, Januszewicz A, Witkowski A, Ruilope LM, Whitbourn R, Bruck H, Downes M, Luscher TF, Jardine AG, Webster MW, Zeller T, Sadowski J, Bartus K, Straley CA, Barman NC, Lee DP, Witteles RM, Bhalla V, Massaro JM and Investigators SH-. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet. 2010;376:1903-1909.

Esler MD, Bohm M, Sievert H, Rump CL, Schmieder RE, Krum H, Mahfoud F and Schlaich MP. Catheter-based renal denervation for treatment of patients with treatment-resistant hypertension: 36 month results from the SYMPLICITY HTN-2 randomized clinical trial. Eur Heart J. 2014;35:1752-1759.

Brandt MC, Mahfoud F, Reda S, Schirmer SH, Erdmann E, Bohm M and Hoppe UC. Renal Sympathetic Denervation Reduces Left Ventricular Hypertrophy and Improves Cardiac Function in Patients With Resistant Hypertension. J Am Coll Cardiol. 2012;59:901-909.

Mahfoud F, Schlaich M, Kindermann I, Ukena C, Cremers B, Brandt MC, Hoppe UC, Vonend O, Rump LC, Sobotka PA, Krum H, Esler M and Bohm M. Effect of Renal Sympathetic Denervation on Glucose Metabolism in Patients With Resistant Hypertension A Pilot Study. Circulation. 2011;123:1940-1946.

Johnson JA. Ethnic differences in cardiovascular drug response: potential contribution of pharmacogenetics. Circulation. 2008;118:1383-93.

Worthley SG, Tsioufis CP, Worthley MI, Sinhal A, Chew DP, Meredith IT, Malaiapan Y and Papademetriou V. Safety and efficacy of amulti-electrode renal sympathetic denervation systemin resistant hypertension: the EnligHTN I trial. Eur Heart J. 2013;34:2132-2140.

Papademetriou V, Tsioufis CP, Sinhal A, Chew DP, Meredith IT, Malaiapan Y, Worthley MI and Worthley SG. Catheter-Based Renal Denervation for Resistant Hypertension 12-Month Results of the EnligHTN I First-in-Human Study Using a Multielectrode Ablation System. Hypertension. 2014;64:565-+.

Chokka RG, Delacroix S, Psaltis PJ, Anavekar NS and Worthley SG. Percutaneous renal denervation and the second generation EnligHTN System. Minerva cardioangiologica. 2014;62:99-104.

Kandzari DE, Bhatt DL, Brar S, Devireddy CM, Esler M, Fahy M, Flack JM, Katzen BT, Lea J, Lee DP, Leon MB, Ma A, Massaro J, Mauri L, Oparil S, O'Neill WW, Patel MR, Rocha-Singh K, Sobotka PA, Svetkey L, Townsend RR and Bakris GL. Predictors of blood pressure response in the SYMPLICITY HTN-3 trial. Eur Heart J. 2014.

Schmiedel L, Traenkner A, Berndt S, Schmiedehausen N, Strasser RH and Schroetter H. The risk to fail in RDN- the unfarourable role of accessory renal arteries. Eur Heart J. 2014;35:231-232.

Doerr O, Liebetrau C, Moellmann H, Rixe J, Troidl C, Hecker F, Szardien S, Willmer M, Hamm C and Nef H. Soluble fms-like tyrosine kinase-1 (sFLT-1) and endothelial Adhesion Molecules (ICAM-1 and VCAM-1) as predictive markers for blood pressure reduction after renal sympathetic denervation. Eur Heart J. 2013;34:495-495.

Dorr O, Liebetrau C, Mollmann H, Gaede L, Troidl C, Rixe J, Hamm C and Nef H. Soluble fms-Like Tyrosine Kinase-1 and Endothelial Adhesion Molecules (Intercellular Cell Adhesion Molecule-1 and Vascular Cell Adhesion Molecule-1) as Predictive Markers for Blood Pressure Reduction After Renal Sympathetic Denervation. Hypertension. 2014;63:984-990.

Krum H, Schlaich M and Esler M. Predictors of Blood Pressure Response Following Catheter Renal Denervation: A Pooled Analysis of the Symplicity Htn-1and Htn-2 Trials. J Am Coll Cardiol. 2013;61:E1380-E1380.

Persu A, Azizi M, Jin Y, Volz S, Rosa J, Elmula FEMF, Pechere-Bertschi A, Burnier M, Mark PB, Elvan A, Renkin J, Sapoval M, Kahan T, Kjeldsen S, Staessen JA and Res ENC. Hyperresponders vs. nonresponder patients after renal denervation: do they differ? J Hypertens. 2014;32:2422-2427.

Prochnau D, Heymel S, Gobel B, Figulla HR and Surber R. Resistant hypertension: multivariate predictors of blood pressure response to renal denervation. Int J Cardiol. 2013;168:3130-2.

Schlaich M. Biomarkers for the Prediction of Blood Pressure Response to Renal Denervation A Long Way to Go. Hypertension. 2014;63:907-908.

Zuern CS, Eick C, Rizas KD, Bauer S, Langer H, Gawaz M and Bauer A. Impaired Cardiac Baroreflex Sensitivity Predicts Response to Renal Sympathetic Denervation in Patients With Resistant Hypertension. J Am Coll Cardiol. 2013;62:2124-2130.

Shewan L.G., Coats A.J.S., Henein M. Requirements for Ethical Publishing in Biomedical Journals. International Cardiovascular Forum Journal. 2015;2:2.



  • There are currently no refbacks.

Copyright (c) 2016 Sinny Delacroix, Ramesh Girish Chokka, Adam Nelson, Stephen J. Nicholls, Stephen G. Worthley

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

ISSN: 2518-6140 (on-line version)